Don’t Miss Out! Special Year End Subscription Available

Learn More

U.S. Market Opportunities for Stenting Technologies

555 Pages | 131 Exhibits | Forecasts Through 2005
market-report-samples/GlobalMarketSegments2.jpg market-report-samples/GlobalMarketSegments3caps.jpg market-report-samples/GlobalMarketSegmentsCaps.jpg
Buy Now

Overview

All of our reports are available via individual purchase or as part of a subscription to our Medtech Pro platform, which includes a full library of reports.

Table of Contents

EXECUTIVE SUMMARY

Stent Technology

Coronary Stents

Peripheral Vascular Stents

Antirestenosis Technologies

Urological Stents

Peripheral Nonvascular Stents

Companies

 

Summary Exhibit 1: U.S. Stent Market by Major Category, 1998-2005

Summary Exhibit 2: Performance Requirements of Stent Implants 

Summary Exhibit 3: Overview of Principal Stent Materials 

Summary Exhibit 4: Coronary Stents, Market Forecast, 1998-2005

Summary Exhibit 5: Peripheral Vascular Stents, Market Forecast, 1998-2005

Summary Exhibit 6: Summary of Antirestenosis Technologies

Summary Exhibit 7: Urological Stents, Market Forecast, 1998-2005

Summary Exhibit 8: Peripheral Nonvascular Stents, Market Forecast, 1998-2005

Summary Exhibit 9: Stents, Supplier Shares, 1999

Summary Exhibit 10: Stents, Supplier Shares by Segment, 1999

 

1.0 STENT TECHNOLOGY

1.1 Stent Materials

1.1.1 Metal Stents 

1.1.1.1 Materials 

1.1.1.1.1 Stainless Steel 

1.1.1.1.2 Nickel-Titanium Alloys 

1.1.1.1.3 Cobalt Alloys

1.1.1.2 Metal Stents and MRI Imaging 

1.1.1.3 Material Developments 

1.1.2 Standard Polymers 

1.1.3 Biodegradable Polymers 

1.1.3.1 Materials 

1.1.3.1.1 Polymer Chemistry

1.1.3.1.2 Polylactic Acid 

1.1.3.1.3 Polyglycolic Acid 

1.1.3.2 Degradation

1.1.3.3 Biocompatibility

1.1.3.4 Self-Expansion

1.1.3.5 Packaging

1.1.3.6 Sterilization

1.1.3.7 Potential Applications 

1.2 Stent Design 

1.2.1 Metal Stents 

1.2.1.1 Balloon-Expandable versus Self-Expanding 

1.2.1.2 Manufacturing Methods 

1.2.1.3 Configurations

1.2.2 Polymer Stents 

1.3 Stent Coatings 

1.3.1 Lubricious Coatings

1.3.2 Radiopaque and Other Imaging Coatings

1.3.2.1 Performance Requirements 

1.3.2.2 Application Methods

1.3.2.3 Product Trends 

1.3.3 Therapeutic Coatings 

1.4 Stent Testing

 

Exhibit 1-1: Performance Requirements of Biomedical Stent Implants

Exhibit 1-2: Overview of Principal Stent Materials

Exhibit 1-3: Metal Stent Materials 

Exhibit 1-4: Selected Polymer Materials Used in Stents 

Exhibit 1-5: Design Criteria for Medical Biodegradable Polymer

Exhibit 1-6: Selected Common Biodegradable Polymers 

Exhibit 1-7: Polymer Degradation Cascade

Exhibit 1-8: Factors Influencing Polymer Degradation 

Exhibit 1-9: Comparison of Two Major Metal Stent Designs 

Exhibit 1-10: Comparison of Stent Designs 

Exhibit 1-11: Restenosis Rates of Coronary Stent Designs in Recent Clinical Study

Exhibit 1-12: Current and Emerging Trends in Stent Coatings 

Exhibit 1-13: Selected Developments in Therapeutic Stent Coatings, 2000 

 

2.0 CORONARY STENTS

2.1 Technique

2.1.1 Stent Deployment 

2.1.1.1 Direct Stenting 

2.1.1.2 Delivery Systems 

2.1.2 Adjuvant Anti-Thrombotic Therapy 

2.1.2.1 Current Regimens 

2.1.2.2 Glycoprotein IIb/IIIa Inhibitors 

2.1.2.3 Coated Stents 

2.1.2.3.1 Biocompatibles International 

2.1.2.3.2 Cordis 

2.1.2.3.3 JOMED

2.1.2.3.4 Medtronic 

2.1.2.3.5 PHYTIS International

2.1.2.3.6 Other Developments 

2.1.3 Stent Imaging

2.1.3.1 Intravascular Ultrasound (IVUS)

2.1.3.2 IVUS-Guided Stent Delivery

2.2 Indications 

2.2.1 Small Vessel Stenting 

2.2.2 Saphenous Vein Graft Stenting

2.2.3 Stenting in Long Lesions/Diffuse Disease 

2.2.4 Stenting in Acute Myocardial Infarction

2.2.5 Left Main Coronary Artery Stenting

2.3 Training Requirements 

2.4 Cost of POBA versus PTCA with Stenting

2.5 Products and Suppliers 

2.5.1 Boston Scientific

2.5.1.1 Medinol NIR Stents

2.5.1.2 Self-Expanding Stents 

2.5.1.3 Emerging Products 

2.5.2 Cook 

2.5.3 Cordis 

2.5.3.1 Palmaz-Schatz Stents 

2.5.3.2 Bx Velocity Stents

2.5.4 Guidant 

2.5.4.1 Multi-Link Duet 

2.5.4.2 Multi-Link Tristar 

2.5.4.3 Multi-Link Ultra

2.5.4.4 Multi-Link Tetra 

2.5.4.5 Multi-Link Penta 

2.5.4.6 Multi-Link Specialty Stents

2.5.5 JOMED

2.5.5.1 JOSTENT Flex

2.5.5.2 Specialty Stents 

2.5.5.2.1 JOSTENT Coronary Stent Graft 

2.5.5.2.2 JOSTENT Bifurcation 

2.5.5.2.3 JOSTENT Sidebranch 

2.5.5.3 U.S. Strategy 

2.5.6 Medtronic 

2.5.6.1 Wiktor Stents 

2.5.6.2 BeStent Products 

2.5.6.3 Arterial Vascular Engineering Products 

2.5.6.4 Current and Emerging Products 

2.6 Procedure Forecasts

2.7 Market Analysis 

2.7.1 Sales Model and Forecast 

2.7.2 Supplier Shares 

 

Exhibit 2-1: Benefits Associated with Direct Stenting 

Exhibit 2-2: Comparison of Three Post-Stenting Antithrombotic Drug Regimens

Exhibit 2-3: Current and Emerging Antithrombotic Coronary Stents, 2000 

Exhibit 2-4: Emerging Indications for Coronary Stenting 

Exhibit 2-5: Chronological Listing of FDA Coronary Stent Approvals: 1998-2000

Exhibit 2-6: CABG Surgery versus Transcatheter Approaches for Revascularization 

Exhibit 2-7: Coronary Stenting by Type, Procedure Forecast, 1998-2005

Exhibit 2-8: Coronary Stenting Procedures by Number of Vessels Treated, 1998-2005 

Exhibit 2-9: Coronary Stents by Type, Market Forecast, 1998-2005

Exhibit 2-10: Stent Usage, Single- versus Multiple-Vessel Stenting, 1998-2005 

Exhibit 2-11: Coronary Stents by Type, Market Forecast, 1998-2005

Exhibit 2-12: Coronary Stents, Supplier Shares, 1998-2000 

 

3.0 PERIPHERAL VASCULAR STENTS

3.1 Overview of Peripheral Vascular Disease

3.1.1 Diagnosis 

3.1.2 Treatment

3.1.3 Role of Peripheral Stenting

3.1.3.1 Off Label Peripheral Vascular Stenting

3.1.3.2 Specialties Performing Peripheral Vascular Stenting 

3.1.3.3 Peripheral Stenting Applications Overview

3.2 Endovascular Repair of Abdominal Aortic Aneurysms 

3.2.1 Diagnosis 

3.2.2 Treatments 

3.2.2.1 Watchful Waiting

3.2.2.2 Open Surgical Repair 

3.2.2.3 Endovascular Stent-Graft Placement

3.2.2.3.1 Outcomes of Open versus Endovascular AAA Repair

3.2.2.3.2 Impact on Patient Indications for AAA Repair 

3.2.3 Stent-Graft Designs

3.2.4 Clinical Applications 

3.2.5 Complications

3.2.6 Clinical Experience

3.2.7 Stent-Grafting for Thoracic Aortic Aneurysms

3.2.8 Products and Suppliers

3.2.8.1 Boston Scientific 

3.2.8.2 Cook

3.2.8.3 Cordis

3.2.8.4 Edwards Lifesciences

3.2.8.5 Endologix

3.2.8.6 Endomed 

3.2.8.7 Guidant 

3.2.8.8 Medtronic

3.2.8.9 Sulzer Medica 

3.2.8.10 TERAMED

3.2.8.11 TriVascular 

3.2.8.12 W.L. Gore & Associates

3.2.9 Emerging Stent-Graft Technologies

3.2.9.1 Thoracic Abdominal Aneurysm Stent-Grafts 

3.2.9.2 Peripheral Vascular Stent-Grafts 

3.2.9.2.1 Boston Scientific 

3.2.9.2.2 JOMED

3.2.9.2.3 W.L. Gore & Associates 

3.2.10 Stent-Graft Procedure Forecasts

3.2.11 Market Analysis

3.3 Stenting in the Management of Stroke

3.3.1 Stroke Etiology and Prevalence 

3.3.2 Types and Causes 

3.3.3 Diagnosis 

3.3.4 Surgical Treatment

3.3.4.1 Carotid Endarterectomy 

3.3.4.1.1 Procedures 

3.3.4.1.2 Indications and Clinical Outcomes 

3.3.4.2 Carotid Artery Stenting 

3.3.4.2.1 Procedure

3.3.4.2.2 Specialties Performing

3.3.4.2.3 Indications and Patient Selection 

3.3.4.2.4 Clinical Studies and Outcomes 

3.3.4.2.5. Role of Distal Embolization 

3.3.4.3 Intracranial Stenting

3.3.4.3.1 Stenting for Intracranial

Atherosclerosisclerosis 

3.3.4.3.2 Intracranial (Cerebral) Aneurysms

3.3.5 Products and Suppliers

3.3.5.1 Carotid Artery Stents

3.3.5.1.1 Boston Scientific 

3.3.5.1.2 C.R. Bard

3.3.5.1.3 Cordis 

3.3.5.1.4 Endotex Interventional Systems

3.3.5.1.5 Guidant 

3.3.5.1.6 JOMED

3.3.5.1.7 Medtronic 

3.3.5.1.8 Scion Cardio-Vascular

3.3.5.2 Distal Protection Devices 

3.3.5.2.1 Filter-Based Devices

3.3.5.2.2 Balloon-Based Devices

3.3.5.2.3 Emerging Applications 

3.3.5.3 Intracranial Stents 

3.3.5.3.1 Guidant 

3.3.5.3.2 Medtronic 

3.3.6 Procedure Forecasts 

3.3.6.1 Carotid Artery Stenting Procedures

3.3.6.2 Use of Distal Protection 

3.3.7 Market Analysis

3.3.7.1 Carotid Artery Stents

3.3.7.2 Distal Protection Devices 

3.4 Femoropopliteal Stenting 

3.4.1 Indications 

3.4.2 Clinical Outcomes

3.4.3 Products 

3.4.3.1 Biocompatibles International

3.4.3.2 IntraTherapeutics 

3.4.4 Procedure Forecasts 

3.4.5 Market Analysis

3.5 Iliac Artery Stenting 

3.5.1 PTA versus Stenting 

3.5.2 Indications and Labeling Requirements 

3.5.3 Clinical Experience and Complications 

3.5.4 Role in Iliac Compression Syndrome

3.5.5 Products and Suppliers

3.5.5.1 Boston Scientific 

3.5.5.2 Cordis

3.5.5.3 Guidant 

3.5.5.4 IntraTherapeutics 

3.5.5.5 JOMED

3.5.5.6 Medtronic

3.5.6 Procedure Forecasts 

3.5.7 Market Analysis

3.6 Renal Artery Stenting 

3.6.1 Renal Artery Stenosis 

3.6.1.1 Diagnosis 

3.6.1.2 Treatment Options

3.6.1.2.1 Renal Artery Bypass Grafting

3.6.1.2.2 Percutaneous Transluminal Renal Angioplasty

3.6.1.2.3 Percutaneous Transluminal Stent Placement 

3.6.1.3 Clinical Outcomes

3.6.2 Emerging Renal Artery Stent Products 

3.6.2.1 C.R. Bard 

3.6.2.2 Guidant 

3.6.2.3 IntraTherapeutics 

3.6.2.4 JOMED

3.6.2.5 Medtronic

3.6.3 Procedure Forecast

3.6.4 Market Analysis

3.7 Transjugular Intrahepatic Portosystemic Shunts

3.7.1 Variceal Bleeding 

3.7.1.1 Treatment Options

3.7.1.2 Decompression Shunt Procedures 

3.7.2 TIPS Technique 

3.7.3 Clinical Results

3.7.4 TIPS Products 

3.7.4.1 Boston Scientific 

3.7.4.2 Other Products 

3.7.4.3 Product Trends 

3.7.5 Procedure Forecasts 

3.7.6 Market Analysis

3.8 Subclavian Stenting

3.8.1 Subclavian Stenting Technique

3.8.2 Clinical Experience

3.8.3 Stent Design

3.8.4 Use of Stent-Grafts 

3.8.5 Products 

3.9 Venous Stenting 

3.9.1 Clinical Experience

3.9.2 Products 

3.9.3 Procedures 

 

Exhibit 3-1: Overview of Peripheral Vascular Disease

Exhibit 3-2: Overview of Peripheral Stenting Applications

Exhibit 3-3: Major Arteries and Veins 

Exhibit 3-4: Treatment Options for Abdominal Aortic Aneurysms

Exhibit 3-5: Comparison of Stent-Graft Designs

Exhibit 3-6: Selected Results of Ongoing Eurostar Trial

Exhibit 3-7: Selected Current and Emerging Endovascular AAA Stent Grafts, 2000

Exhibit 3-8: Selected Stent-Grafts Under Development for Thoracic Aortic Aneurysms and Peripheral Vessel Aneurysms

Exhibit 3-9: Drivers and Limiters of Endovascular AAA Repair 

Exhibit 3-10: Endovascular AAA Repairs, Procedure Forecast, 1998-2005

Exhibit 3-11: AAA Stent-Graft Systems, Market Forecast, 1998-2005

Exhibit 3-12: AAA Stent-Graft Systems, Supplier Shares, 1999

Exhibit 3-13: Overview of Stroke in the U.S.

Exhibit 3-14: Emerging Indications for Carotid Artery Stenting 

Exhibit 3-15: Characteristics of Ideal Carotid Artery Stent 

Exhibit 3-16: Selected Carotid Artery Stents Under Development, 2000

Exhibit 3-17: Comparison of Distal Protection Devices, 2000 

Exhibit 3-18: Clinical Results from the Sapphenous Vein Graft Angioplasty Free of Emboli, Randomized (SAFER) Trial 

Exhibit 3-19: Carotid Artery Stenting, Procedure Forecast, 1998-2005 

Exhibit 3-20: Distal Protection, Procedure Forecast, 1998-2005

Exhibit 3-21: Carotid Artery Stents, Market Forecast, 1998-2005 

Exhibit 3-22: Distal (Embolic) Protection Devices, Market Forecast, 1998-2005

Exhibit 3-23: Roles of Diabetes in Femoropopliteal Artery Disease 

Exhibit 3-24: Femoropopliteal Artery Stenting, Procedure Forecast, 1998-2005 

Exhibit 3-25: Femoropopliteal Stents, Market Forecast, 1998-2005 

Exhibit 3-26: Selected Current and Emerging Iliac Artery Stents, 2000

Exhibit 3-27: Clinical Results Comparison: Wallstent vs. Palmaz Schatz Iliac Stents 

Exhibit 3-28: Iliac Artery Stenting, Procedure Forecast, 1998-2005 

Exhibit 3-29: Iliac Artery Stents, Market Forecast, 1998-2005 

Exhibit 3-30: Iliac Artery Stents, Supplier Shares, 1999 

Exhibit 3-31: Selected Emerging Renal Artery Stents, 2000 

Exhibit 3-32: Renal Artery Stenting, Procedure Forecast, 1998-2005

Exhibit 3-33: Renal Artery Stents, Market Forecast, 1998-2005 

Exhibit 3-34: Transjugular Intrahepatic Portosystemic Shunts (TIPS), Procedure Forecast, 1998-2005 

Exhibit 3-35: Transjugular Intrahepatic Portosystemic Shunt (TIPS) Stents, Market Forecast, 1998-2005

 

4.0 ANTIRESTENOSIS TECHNOLOGIES

4.1 Mechanisms

4.2 Primary versus In-Stent Restenosis 

4.3 Overview of Antirestenosis Technologies 

4.4 Antirestenosis Stents 

4.4.1 Radioactive Stents 

4.4.1.1 Clinical Experience 

4.4.1.2 Products and Suppliers 

4.4.1.2.1 InnerDyne

4.4.1.2.2 Cordis/Isostent

4.4.1.2.3 Guidant 

4.4.1.2.4 Implant Sciences

4.4.1.2.5 Theragenics 

4.4.1.3 Other Developments

4.4.1.3.1 On-Site Radioactive Stent Preparation

4.4.1.3.2 Intravascular Activation Brachytherapy

4.4.1.4 Market Limiters

4.4.2 Drug Eluting Stents

4.4.2.1 Sirolimus (Cordis/Wyeth-Ayerst)

4.4.2.2 Paclitaxel

4.4.2.2.1 Angiotech Pharmaceuticals (Boston Scientific, Cook)

4.4.2.2.2 Quanam Medical

4.4.2.3 Gene Therapy Stents 

4.4.2.4 Biocompatibles International

4.4.2.5 Endovasc

4.4.2.6 Other Stent Coatings 

4.4.2.7 Biodegradable Stents

4.4.2.7.1 Igaki-Tamai Stent 

4.4.2.7.2 Other Biodegradable Stent Programs

4.4.3 Other Developments 

4.5 Competing Antirestenosis Technologies

4.5.1 Intravascular Brachytherapy 

4.5.1.1 Radiation Sources

4.5.1.2 Products and Suppliers 

4.5.1.2.1 Guidewire/Sourcetrain Systems

4.5.1.2.2 Balloon-Based Systems 

4.5.1.2.3 X-Ray Catheter Delivery Systems

4.5.1.2.4 Intracoronary Infiltrating Catheter 

4.5.2 Drug Therapy

4.5.3 Gene Therapy

4.5.4 Energy-Based Therapies 

4.5.4.1 Cryoablation

4.5.4.2 Intravascular Sonotherapy

4.5.4.2.1 PharmaSonics 

4.5.4.2.2 Angiosonics 

4.5.4.3 Photodynamic Therapy 

 

Exhibit 4-1: Mechanisms of Restenosis

Exhibit 4-2: Summary of Antirestenosis Technologies 

Exhibit 4-3: Overview of Radioactive Stents 

Exhibit 4-4: Selected Radioactive Stent Programs, 2000

Exhibit 4-5: Overview of Drug-Eluting Stents 

Exhibit 4-6: Selected Drug-Eluting Stent Programs, 2000 

Exhibit 4-7: Comparison of Intravascular Brachytherapy Approaches

Exhibit 4-8: Intravascular Brachytherapy Products and Suppliers, 2000

Exhibit 4-9: Selected Gene Therapy Approaches to Treating Restenosis 

Exhibit 4-10: Selected Photodynamic Therapy Programs for Restenosis, 2000 

 

5.0 UROLOGICAL STENTS

5.1 Ureteral Stents 

5.1.1 Clinical Applications 

5.1.2 Stent Design

5.1.3 Stent Materials 

5.1.4 Stent Coatings

5.1.5 Stent Sizing

5.1.6 Placement Techniques 

5.1.6.1 Open Surgical Placement 

5.1.6.2 Retrograde Placement 

5.1.6.3 Percutaneous Antegrade Placement

5.1.7 Implantation Time

5.1.8 Stent Removal

5.1.9 Products and Suppliers

5.1.9.1 Applied Medical Resources Corporation

5.1.9.2 Bard Urology

5.1.9.3 Circon Surgitek 

5.1.9.4 Cook Urological

5.1.9.5 Microvasive Urology

5.1.9.6 Rusch International 

5.1.9.7 UroSurge Corporation

5.1.10 Product Developments 

5.1.10.1 Metallic Ureteral Stents

5.1.10.2 Biodegradable Ureteral Stents

5.1.11 Procedure Forecasts 

5.1.12 Market Analysis

5.1.13 Supplier Shares 

5.2 Urethral Stents

5.2.1 Current and Potential Applications 

5.2.1.1 Urethral Stricture

5.2.1.2 Benign Prostatic Hyperplasia 

5.2.1.2.1 Prevalence 

5.2.1.2.2 Treatment

5.2.1.2.3 Potential Role of Stenting

5.2.1.3 Prostate Cancer 

5.2.1.4 Prostatitis 

5.2.1.5 Other Applications 

5.2.2 Stent Characteristics 

5.2.3 Products and Suppliers

5.2.3.1 American Medical Systems

5.2.3.1.1 Insertion

5.2.3.1.2 Configurations 

5.2.3.1.3 Regulatory Approvals 

5.2.3.1.4 Clinical Experience

5.2.3.1.5 Pricing and Reimbursement

5.2.3.1.6 Product Developments

5.2.3.2 ASI

5.2.3.3 Biocompatibles Limited 

5.2.3.4 Bionx Implants

5.2.3.4.1 Insertion

5.2.3.4.2 Performance Challenges 

5.2.3.4.3 Regulatory Status

5.2.3.4.4 Clinical Experience

5.2.3.4.5 Marketing and Distribution

5.2.3.4.6 Product Developments

5.2.3.5 Boston Scientific Corporation 

5.2.3.5.1 Ultraflex

5.2.3.5.2 Trestle Prostatic Bridge Catheter 

5.2.3.6 ContiCare Medical 

5.2.3.6.1 Design

5.2.3.6.2 Insertion and Removal 

5.2.3.6.3 Clinical Experience

5.2.3.6.4 Regulatory Status

5.2.3.6.5 Marketing and Distribution

5.2.3.7 CR Bard 

5.2.3.7.1 Barnes Stent

5.2.3.7.2 Memotherm

5.2.3.8 Endocare 

5.2.3.8.1 Insertion and Removal 

5.2.3.8.2 Clinical Experience

5.2.3.8.3 Marketing and Distribution

5.2.3.8.4 Reimbursement

5.2.3.8.5 Long-Term Strategy (ThermaStent)

5.2.3.9 Engineers & Doctors A/S

5.2.3.9.1 Insertion and Removal 

5.2.3.9.2 Clinical Experience

5.2.3.9.3 Indications 

5.2.3.9.4 Pricing 

5.2.3.10 InjecTx 

5.2.3.11 IntraTherapeutics 

5.2.3.11.1 UroCoil Stents 

5.2.3.11.2 Clinical Experience

5.2.3.11.3 ProstaCoil Stent 

5.2.3.11.4 Marketing and Distribution

5.2.3.12 Porges S.A.

5.2.4 Product Developments 

5.2.5 Procedure Forecasts 

5.2.6 Market Analysis

 

Exhibit 5-1: Clinical Applications for Ureteral Stents

Exhibit 5-2: Design Specifications for Ureteral Stents 

Exhibit 5-3: Selected Ureteral Stent Materials 

Exhibit 5-4: Selected Hydrophilic Ureteral Stent Coatings 

Exhibit 5-5: Placement Techniques Used in Ureteral Stenting 

Exhibit 5-6: Bard Urological Ureteral Stents, 2000

Exhibit 5-7: Circon Surgitek Ureteral Stents, 2000 

Exhibit 5-8: Cook Urological Ureteral Stents, 2000

Exhibit 5-9: Microvasive Urology Ureteral Stents, 2000

Exhibit 5-10: Developments in Metallic and Biodegradable Ureteral Stents

Exhibit 5-11: Ureteral Stenting, Procedure Forecast, 1998-2005 

Exhibit 5-12: Ureteral Stents, Market Forecast, 1998-2005

Exhibit 5-13: Ureteral Stents, Supplier Shares, 1999

Exhibit 5-14: Current and Emerging Applications for Urethral Stents, 2000 

Exhibit 5-15: Design Specifications for Ideal Urethral Stent

Exhibit 5-16: Comparison of Current and Emerging Urethral Stents, 2000

Exhibit 5-17: Urethral Stenting, Procedure Forecast, 1998-2005 

Exhibit 5-18: Urethral Stents, Market Forecast, 1998-2005 

 

6.0 PERIPHERAL NONVASCULAR STENTS

6.1 Biliary Stents 

6.1.1 Clinical Indications 

6.1.2 Implantation Technique 

6.1.3 Materials and Technology

6.1.3.1 Plastic Biliary Stents 

6.1.3.2 Metal Biliary Stents

6.1.3.2.1 Balloon-Expandable Stents

6.1.3.2.2 Self-Expanding Metal Stents 

6.1.3.3 Product Trends 

6.1.4 Clinical Experience

6.1.5 Stent Removal and Patency Issues 

6.1.6 Products 

6.1.6.1 Angiodynamics 

6.1.6.2 C.R. Bard 

6.1.6.3 Boston Scientific Microvasive 

6.1.6.4 Cordis

6.1.6.5 Guidant 

6.1.6.6 IntraTherapeutics 

6.1.6.7 Medtronic

6.1.6.8 Wilson-Cook Medical 

6.1.6.9 Other Suppliers 

6.1.7 Procedure Forecasts 

6.1.8 Market Analysis

6.1.9 Supplier Shares 

6.2 Colorectal Stents

6.2.1 Clinical Indications 

6.2.2 Implantation Technique 

6.2.3 Clinical Experience

6.2.4 Products and Technology

6.2.4.1 Metal Stents 

6.2.4.1.1 C.R. Bard

6.2.4.1.2 Boston Scientific Microvasive

6.2.4.1.3 IntraTherapeutics

6.2.4.1.4 Wilson-Cook Medical

6.2.4.2 Product Trends 

6.2.5 Procedure Forecast

6.2.6 Market Analysis

6.2.7 Supplier Shares 

6.3 Esophageal Stents

6.3.1 Stenting in Esophageal Cancer

6.3.2 Implantation Technique 

6.3.3 Clinical Experience

6.3.4 Products and Technology

6.3.4.1 Plastic Stents 

6.3.4.1.1 Boston Medical Products 

6.3.4.1.2 Hood Laboratories 

6.3.4.2 Metal Stents 

6.3.4.2.1 C.R. Bard

6.3.4.2.2 Boston Scientific Microvasive

6.3.4.2.3 IntraTherapeutics

6.3.4.2.4 Wilson-Cook Medical

6.3.4.3 Product Trends 

6.3.5 Procedure Forecast

6.3.6 Market Analysis

6.3.7 Supplier Shares 

6.4 Tracheal Stents 

6.4.1 Clinical Indications 

6.4.2 Implantation Technique 

6.4.3 Clinical Experience

6.4.4 Products and Technology

6.4.4.1 Plastic Stents 

6.4.4.1.1 Boston Medical Products 

6.4.4.1.2 Bryan 

6.4.4.1.3 Hood Laboratories 

6.4.4.1.4 Transtracheal Systems 

6.4.4.2 Metal Stents 

6.4.4.2.1 Boston Scientific Microvasive

6.4.4.2.2 IntraTherapeutics

6.4.4.2.3 Other Suppliers 

6.4.4.3 Product Trends 

6.4.5 Procedure Forecasts 

6.4.6 Market Analysis

6.4.7 Supplier Shares 

6.5 Other Nonvascular Stents 

6.5.1 Vaginal Stenting 

6.5.1.1 Clinical Experience 

6.5.1.2 Products 

6.5.1.2.1 Intelligence Engineering 

6.5.1.2.2 Silimed 

6.5.1.3 Procedure Forecasts 

6.5.1.4 Market Forecast

6.5.1.5 Supplier Shares 

6.5.2 Nasal Stenting

6.5.2.1 Clinical Experience 

6.5.2.2 Products 

6.5.2.2.1 Bivona Medical Technologies 

6.5.2.2.2 Boston Medical Products 

6.5.2.2.3 InHealth

6.5.2.2.4 Lubrelastic 

6.5.2.2.5 Medtronic Xomed

6.5.2.2.6 Smith & Nephew

6.5.2.3 Metal and Bioresorbable Stents

6.5.2.4 Procedure Forecast 

6.5.2.5 Market Analysis 

6.5.2.6 Supplier Shares 

6.5.3 Palatal Stenting (Aquaplast)

 

Exhibit 6-1: Liver, Biliary and Pancreatic Cancer Data, 1998-2005

Exhibit 6-2: Other Potential Indications for Biliary Stenting

Exhibit 6-3: Comparison of Plastic and Metal Biliary Stents 

Exhibit 6-4: Selected Plastic Biliary Stents, 2000 

Exhibit 6-5: Selected Metal Biliary Stents, 2000

Exhibit 6-6: Biliary Stenting, Procedure Forecast, 1998-2005 

Exhibit 6-7: Biliary Stents, Market Forecast, 1998-2005 

Exhibit 6-8: Biliary Stents, Supplier Shares, 1999 

Exhibit 6-9: Trend in Colorectal Cancer, 1998-2005

Exhibit 6-10: Selected Metal Colorectal Stents, 2000 

Exhibit 6-11: Colorectal Stenting, Procedure Forecast, 1998-2005

Exhibit 6-12: Colorectal Stents, Market Forecast, 1998-2005 

Exhibit 6-13: Comparison of Plastic versus Metal Esophageal Stents

Exhibit 6-14: Selected Plastic and Metal Esophageal Stents, 2000 

Exhibit 6-15: Esophageal Stenting, Procedure Forecast, 1998-2005 

Exhibit 6-16: Esophageal Stents, Market Forecast, 1998-2005 

Exhibit 6-17: Esophageal Stents, Supplier Shares, 1999 

Exhibit 6-18: Indications for Tracheal Stenting

Exhibit 6-19: Comparison of Plastic and Metal Airway Stents 

Exhibit 6-20: Selected Plastic Airway Stents, 2000

Exhibit 6-21: Selected Metal Airway Stents, 2000

Exhibit 6-22: Tracheal Stenting, Procedure Forecast, 1998-2005

Exhibit 6-23: Tracheal Stents, Market Forecast, 1998-2005

Exhibit 6-24: Tracheal Stents, Supplier Shares, 1999

Exhibit 6-25: Comparison of Inflatable and Solid Vaginal Stents 

Exhibit 6-26: Selected Vaginal Stents, 2000 

Exhibit 6-27: Vaginal Stenting, Procedure Forecasts, 1998-2005 

Exhibit 6-28: Vaginal Stents, Market Forecast, 1998-2005

Exhibit 6-29: Vaginal Stents, Supplier Shares, 1999

Exhibit 6-30: Selected Nasal and Palatal Stents, 2000

Exhibit 6-31: Nasal Stenting, Procedure Forecast, 1998-2005 

Exhibit 6-32: Nasal Stents, Market Forecast, 1998-2005 

Exhibit 6-33: Nasal Stents, Supplier Shares, 1999 

 

7. COMPANY PROFILES 

7.1 American Medical Systems Holdings

7.1.1 Financial Results

7.1.2 Organization of Business 

7.1.3 Participation in Stent Market 

7.2 Angiotech Pharmaceuticals 

7.2.1 Financial Results

7.2.2 Participation in Stent Market 

7.2.3 Other Activities

7.3 C.R. Bard

7.3.1 Financial Results

7.3.2 Organization of Business 

7.3.3 Participation in Stent Market 

7.3.4 Other Activities

7.4 Biocompatibles International plc 

7.4.1 Financial Results

7.4.2 Organization of Business 

7.4.3 Participation in Stent Market 

7.5 Bionx Implants 

7.5.1 Financial Results

7.5.2 Participation in Stent Market 

7.6 Boston Scientific Corporation 

7.6.1 Financial Results

7.6.2 Organization of Business 

7.6.3 Participation in Stent Market 

7.6.4 Patent Litigation

7.6.5 Other Activities

7.7 Bryan Corporation

7.8 Circon Corporation (Maxxim Medical) 

7.8.1 Participation in Stent Market 

7.8.2 Financial Results

7.8.3 Other Information 

7.9 Cook Group

7.9.1 Participation in Stent Market 

7.9.2 Patent Litigation

7.9.3 Financial Assessment

7.10 Engineers & Doctors A/S (Ltd.) 

7.11 Endocare

7.11.1 Financial Results

7.11.2 Organization of Business 

7.11.3 Participation in Stent Market 

7.11.4 Other Activities

7.12 Guidant Corporation

7.12.1 Financial Results

7.12.2 Participation in Stent Market 

7.12.3 Patent Litigation

7.12.4 Other Activities

7.13 E. Benson Hood Laboratories

7.14 Implant Sciences Corporation

7.14.1 Financial Results

7.14.2 Participation in Stent Market 

7.14.3 Other Activities

7.15 InHealth

7.16 IntraTherapeutics

7.16.1 Company Overview

7.16.2 Participation in Stent Market 

7.16.3 Other Activities

7.17 Johnson & Johnson

7.17.1 Financial Results

7.17.2 Organization of Business 

7.17.3 Participation in Stent Market 

7.17.4 Patent Litigation

7.18 JOMED NV

7.18.1 Financial Results

7.18.2 Organization of Business 

7.18.3 Positioning Activities

7.18.4 Other Activities

7.19 Medtronic 

7.19.1 Financial Results

7.19.2 Organization of Business 

7.19.3 Acquisitions 

7.19.4 Participation in Stent Market 

7.19.5 Patent Litigation

7.20 Sulzer Medica

7.20.1 Organization of Business 

7.20.2 Financial Results

7.20.3 Participation in Stent Market 

7.20.4 Strategic Acquisitions and Agreements

7.21 TERAMED

 

APPENDIX: LIST OF COMPANIES

Companies Covered

American Medical Systems Holdings

Angiotech Pharmaceuticals 

Biocompatibles International plc 

Bionx Implants 

Boston Scientific Corporation 

Bryan Corporation

C.R. Bard

Circon Corporation (Maxxim Medical) 

Cook Group

E. Benson Hood Laboratories

Endocare

Engineers & Doctors A/S (Ltd.) 

Guidant Corporation

Implant Sciences Corporation

 InHealth

IntraTherapeutics

Johnson & Johnson

JOMED NV

Medtronic 

Sulzer Medica

TERAMED